WO2010150082A3 - Use of chromogranin a and peptidic derivatives thereof in the treatment of inflammation - Google Patents

Use of chromogranin a and peptidic derivatives thereof in the treatment of inflammation Download PDF

Info

Publication number
WO2010150082A3
WO2010150082A3 PCT/IB2010/001522 IB2010001522W WO2010150082A3 WO 2010150082 A3 WO2010150082 A3 WO 2010150082A3 IB 2010001522 W IB2010001522 W IB 2010001522W WO 2010150082 A3 WO2010150082 A3 WO 2010150082A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
chromogranin
inflammation
peptidic
derivatives
Prior art date
Application number
PCT/IB2010/001522
Other languages
French (fr)
Other versions
WO2010150082A2 (en
Inventor
Fabrizio Marcucci
Angelo Corti
Barbara Colombo
Anna Maria Gasparri
Cristiano Rumio
Marco Palazzo
Laura Zanobbio
Original Assignee
Universita' Degli Studi Di Milano
Fondazione Centro San Raffaele Del Monte Tabor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universita' Degli Studi Di Milano, Fondazione Centro San Raffaele Del Monte Tabor filed Critical Universita' Degli Studi Di Milano
Publication of WO2010150082A2 publication Critical patent/WO2010150082A2/en
Publication of WO2010150082A3 publication Critical patent/WO2010150082A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

The invention concerns the use of chromogranin A, its peptidic derivatives and their non-peptidic peptidomimetic derivatives in the treatment and prevention of inflammatory pathologies of the digestive system, in the treatment and/or prevention of diseases such as Crohn's disease, ulcerative colitis and, more generally, chronic bowel disease and inflammatory diseases of the respiratory system.
PCT/IB2010/001522 2009-06-25 2010-06-24 Use of chromogranin a and of peptidic derivatives thereof in the treatment of inflammation WO2010150082A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT001125A ITMI20091125A1 (en) 2009-06-25 2009-06-25 USE OF CROMOGRANIN A AND ITS PEPTIDIC DERIVATIVES IN THE TREATMENT OF CHANNEL INFLAMMATIONS
ITMI2009A001125 2009-06-25

Publications (2)

Publication Number Publication Date
WO2010150082A2 WO2010150082A2 (en) 2010-12-29
WO2010150082A3 true WO2010150082A3 (en) 2011-05-19

Family

ID=42321132

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2010/001522 WO2010150082A2 (en) 2009-06-25 2010-06-24 Use of chromogranin a and of peptidic derivatives thereof in the treatment of inflammation

Country Status (2)

Country Link
IT (1) ITMI20091125A1 (en)
WO (1) WO2010150082A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014188373A1 (en) * 2013-05-24 2014-11-27 University Of Manitoba Chromogranin-a-derived polypeptides and methods of use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000064939A2 (en) * 1999-04-26 2000-11-02 Institut National De La Sante Et De La Recherche Medicale Peptides derived from vasostatin i and the use thereof as anti-fungal agents
WO2003020301A1 (en) * 2001-08-31 2003-03-13 Fondazione Centro San Raffaele Del Monte Tabor Chromogranin a and fragments thereof for the treatment of diseases involving increased vascular permeability
WO2009053725A2 (en) * 2007-10-27 2009-04-30 The Queen's University Of Belfast Peptides and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000064939A2 (en) * 1999-04-26 2000-11-02 Institut National De La Sante Et De La Recherche Medicale Peptides derived from vasostatin i and the use thereof as anti-fungal agents
WO2003020301A1 (en) * 2001-08-31 2003-03-13 Fondazione Centro San Raffaele Del Monte Tabor Chromogranin a and fragments thereof for the treatment of diseases involving increased vascular permeability
WO2009053725A2 (en) * 2007-10-27 2009-04-30 The Queen's University Of Belfast Peptides and uses thereof

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BLOIS A ET AL: "The chromogranin A peptide vasostatin-I inhibits gap formation and signal transduction mediated by inflammatory agents in cultured bovine pulmonary and coronary arterial endothelial cells", REGULATORY PEPTIDES, vol. 135, no. 1-2, 15 July 2006 (2006-07-15), ELSEVIER SCIENCE BV, NL, pages 78 - 84, XP025033136, ISSN: 0167-0115, [retrieved on 20060715], DOI: 10.1016/J.REGPEP.2006.04.007 *
FERRERO ELISABETTA ET AL: "Chromogranin A protects vessels against tumor necrosis factor alpha-induced vascular leakage", FASEB JOURNAL, vol. 18, no. 3, 1 March 2004 (2004-03-01), pages 554 - 556, XP002592934 *
GONZALEZ-REY ET AL: "Anti-inflammatory neuropeptide receptors: new therapeutic targets for immune disorders?", TRENDS IN PHARMACOLOGICAL SCIENCES, vol. 28, no. 9, 1 September 2007 (2007-09-01), ELSEVIER, HAYWARTH, GB, pages 482 - 491, XP022234216, ISSN: 0165-6147, DOI: 10.1016/J.TIPS.2007.07.001 *
HUEGEL RAINER ET AL: "Novel anti-inflammatory properties of the angiogenesis inhibitor vasostatin", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 127, no. 1, 1 January 2007 (2007-01-01), pages 65 - 74, XP002592933 *
KONECKI D S ET AL: "THE PRIMARY STRUCTURE OF HUMAN CHROMOGRANIN A AND PANCREASTATIN", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 262, no. 35, 15 December 1987 (1987-12-15), AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, INC, US, pages 17026 - 17030, XP000616262, ISSN: 0021-9258 *
ORR DAVID F ET AL: "The spectrum of endogenous human chromogranin A-derived peptides identified using a modified proteomic strategy", PROTEOMICS, vol. 2, no. 11, 1 November 2002 (2002-11-01), WILEY - VCH VERLAG, WEINHEIM, DE, pages 1586 - 1600, XP002526290, ISSN: 1615-9853, DOI: 10.1002/1615-9861(200211)2:11<1586::AID-PROT1586>3.0.CO;2-K *
SCIOLA VALENTINA ET AL: "Plasma chromogranin a in patients with inflammatory bowel disease", INFLAMMATORY BOWEL DISEASES, vol. 15, no. 6, 1 June 2009 (2009-06-01), pages 867 - 871, XP002592932 *

Also Published As

Publication number Publication date
ITMI20091125A1 (en) 2010-12-26
WO2010150082A2 (en) 2010-12-29

Similar Documents

Publication Publication Date Title
MY148872A (en) Use of bifidobacterium longum for the prevention and treatment of inflammation
IL200766A (en) Use of antigen-mhc complex for the preparation of medicaments for the prevention and treatment of autoimmune conditions
WO2009114776A3 (en) Integrin targeting agents and in-vivo and in-vitro imaging methods using the same
EP2087094A4 (en) Lactobacillus fermentum ess-1, dsm17851 and its use for the treatment and/or prevention of candidiasis and urinary tracrinfections
ZA201304638B (en) Composition for use in the prevention and /or treatment of skin condition and skin diseases.
PL2118300T3 (en) Prevention and treatment of synucleinopathic and amyloidogenic disease
EP2650002A4 (en) Bifidobacterium cect 7765 and use thereof in the prevention and/or treatment of excess weight, obesity and related pathologies
GB0610350D0 (en) prevention and/or treatment of neuodegenerative disorders
PL2219658T3 (en) Composition based on probiotic bacteria in association with a prebiotic and use thereof in the prevention and/or treatment of respiratory pathologies and/or infections and in the improvement of intestinal functionality
PT2388317T (en) A gene encoding a human glucokinase mutant, and uses thereof in the treatment or prevention of disease
HK1138622A1 (en) Prevention and treatment of synucleinopathic and amyloidogenic disease
WO2010129347A3 (en) Compositions and methods for the treatment of disorders involving epithelial cell apoptosis
EP2019098A4 (en) Suppressor of expression of mcp-1, and ameliorating agent for inflammatory disease, pharmaceutical, supplement, food, beverage or food additive using the suppressor
WO2011050379A9 (en) Use of gstp1
EP2231148A4 (en) Pharmaceutical composition for the treatment and prevention of cardiac disease
EP1843781A4 (en) Composition for prevention, treatment and diagnosis of chronic inflammatory airway diseases
EP2231146A4 (en) Pharmaceutical composition for the treatment and prevention of glaucoma
WO2010150082A3 (en) Use of chromogranin a and peptidic derivatives thereof in the treatment of inflammation
HK1130209A1 (en) Therapeutic and/or ameliorating agent for disseminated intravascular coagulation
WO2008022807A3 (en) Lipoxin a4 analogs for the treatment and prevention of intestinal fibrosis
EP2508192A4 (en) Agent for the treatment and prevention of diseases of the male urogenital system
EP2127645A4 (en) Pharmaceutical agent for prevention and/or treatment of lower urinary tract symptom
WO2008050363A3 (en) Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of autoimmune diseases
MX2009004237A (en) Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of allergies.
GB0612748D0 (en) Treatment and/or prevention of inflammatory lung disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10740710

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10740710

Country of ref document: EP

Kind code of ref document: A2